Indeed, a prior study suggested that overexpression of a single ETS TF confers resistance to MEKi trametinib in KRAS mutant pancreatic cancer, while suppression of ETV1, ETV4, or ETV5 alone strongly decreased the resistance [47]. This evidence concerns the gene ETV4 and pancreatic neoplasm.